• Immunization against measles, mumps & rubella:
    • 19-49 years old: SC 0.5mL *1-2 doses
    • 2nd dose administered 28 days later for high risk adults

Injection:

≥3.4 log10 CCID50

≥4.2 log10 CCID50

≥3.3 log10 CCID50

  • Inject SC into outer aspect of upper arm
  • Reconstituted solution should be discarded if not used within 8 hours

Live vaccine

It induces antibody formation

  • Arthralgia
  • Arthritis
  • Fever
  • Urticaria
  • Rash
  • Measles-like rash
  • Pruritus
  • Injection site reaction
  • Headache
  • Dizziness
  • Malaise
  • Irritability
  • Hypersensitivity to components/class
  • Immunocompromised patients
  • HIV infection with CD4 <15% or <200
  • Active untreated TB infection
  • Acute febrile illness
  • Pregnancy
  • Belimumab
  • Certolizumab pegol
  • Ibrutinib
  • Ifosfamide
  • Ixekizumab
  • Lomustine
  • Mechlorethamine
  • Melphalan
  • Methotrexate
  • Onasemnogene abeparvovec
  • Oxaliplatin
  • Procarbazine
  • Secukinumab
  • Ustekinumab

                          Drug Status

Availability Prescription only
Pregnancy Contraindicated
Breastfeeding Weigh risk vs benefit
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Measles Mumps And Rubella Vaccine FDC Injection 1D, 10D Serum Institute of India Sai Pharma
Priorix FDC Injection 1D GSK Ltd GSK Ltd